Literature DB >> 22993578

Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1.

Jerzy Jankun1, Ewa Skrzypczak-Jankun.   

Abstract

In the present study, we present a 60-year-old woman of American Indian descent with a life-long history of bleeding diathesis. She had a history of recurrent and prolonged bleeding such as mild epistaxis, gingival bleeding and microscopic hematurias. She also experienced a severe bleeding event after surgery. The patient had a large family with a history of a tendency of bleeding, severe in some cases. Hemostatic screening studies revealed no abnormalities, which could explain the bleeding tendency. Clot formation of sodium-citrated blood was analyzed by thromboelastography, which suggested a low platelet count or plasminogen activator inhibitor-1 (PAI-1) deficiency. However, her platelet count was slightly elevated. Subsequent sequencing of the PAI-1 gene revealed a heterozygous Ala15Thr mutation in the signal peptide. This type of deficiency is related to dynamics of PAI-1 secretion rather than its low levels or activity. We concluded that the PAI-1 mutation was likely the etiology of the bleeding diathesis in this patient.

Entities:  

Year:  2010        PMID: 22993578      PMCID: PMC3445900          DOI: 10.3892/etm_00000090

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  16 in total

Review 1.  Yin and yang of the plasminogen activator inhibitor.

Authors:  Jerzy Jankun; Ewa Skrzypczak-Jankun
Journal:  Pol Arch Med Wewn       Date:  2009-06

2.  A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide.

Authors:  Zi Yan Zhang; Zhao Yue Wang; Ning Zheng Dong; Xia Bai; Wei Zhang; Chang Geng Ruan
Journal:  Blood Coagul Fibrinolysis       Date:  2005-01       Impact factor: 1.276

3.  Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.

Authors:  M E Carr; C Krishnamurti; B M Alving
Journal:  Thromb Haemost       Date:  1992-01-23       Impact factor: 5.249

4.  Enhancement of plasma fibrinolysis in vitro by jararhagin, the main haemorrhagic metalloproteinase in Bothrops jararaca venom.

Authors:  M Sugiki; M Maruyama; E Yoshida; H Mihara; A S Kamiguti; D G Theakston
Journal:  Toxicon       Date:  1995-12       Impact factor: 3.033

5.  In vitro effects of propofol on blood coagulability and fibrinolysis by the use of thromboelastograph technique.

Authors:  S Kohro; M Yamakage; T Omote; A Namiki
Journal:  Acta Anaesthesiol Scand       Date:  1999-02       Impact factor: 2.105

Review 6.  Plasminogen activator inhibitor type 1 deficiency.

Authors:  R Mehta; A D Shapiro
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

7.  Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.

Authors:  Anna Agren; Björn Wiman; Sam Schulman
Journal:  Blood Coagul Fibrinolysis       Date:  2007-10       Impact factor: 1.276

8.  Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.

Authors:  Jerzy Jankun; Ansari M Aleem; Steven H Selman; Ewa Skrzypczak-Jankun; Wieslawa Lysiak-Szydlowska; Nicholas Grafos; Hugh J L Fryer; Robert S Greenfield
Journal:  Int J Mol Med       Date:  2007-11       Impact factor: 4.101

9.  Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life.

Authors:  Jerzy Jankun; Ansari M Aleem; Radosław Struniawski; Wiesława Lysiak-Szydłowska; Steven H Selman; Ewa Skrzypczak-Jankun
Journal:  Pharmacol Rep       Date:  2009 Jul-Aug       Impact factor: 3.024

10.  Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.

Authors:  R R Schleef; D L Higgins; E Pillemer; L J Levitt
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

View more
  3 in total

1.  Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.

Authors:  Daniel Glenn Kindell; Rick Wayne Keck; Jerzy Jankun
Journal:  Exp Ther Med       Date:  2015-04-01       Impact factor: 2.447

Review 2.  Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).

Authors:  Marzena Wyganowska-Świątkowska; Mateusz Tarnowski; Daniel Murtagh; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Int J Mol Med       Date:  2018-11-07       Impact factor: 4.101

3.  Revisiting Hartert's 1962 Calculation of the Physical Constants of Thrombelastography.

Authors:  Gerald Hochleitner; Ken Sutor; Caroline Levett; Harald Leyser; Christoph J Schlimp; Cristina Solomon
Journal:  Clin Appl Thromb Hemost       Date:  2015-01-01       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.